Meeder Asset Management Inc. lessened its position in Charles River Laboratories Intl. Inc (NYSE:CRL) by 72.0% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,611 shares of the medical research company’s stock after selling 4,139 shares during the quarter. Meeder Asset Management Inc.’s holdings in Charles River Laboratories Intl. were worth $176,000 as of its most recent filing with the SEC.

Several other large investors have also recently modified their holdings of the stock. Ameritas Investment Partners Inc. lifted its position in shares of Charles River Laboratories Intl. by 2.1% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 14,256 shares of the medical research company’s stock valued at $1,442,000 after acquiring an additional 291 shares in the last quarter. Public Employees Retirement System of Ohio lifted its position in shares of Charles River Laboratories Intl. by 1.5% in the 2nd quarter. Public Employees Retirement System of Ohio now owns 22,383 shares of the medical research company’s stock valued at $2,264,000 after acquiring an additional 330 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. lifted its position in shares of Charles River Laboratories Intl. by 69.0% in the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,342 shares of the medical research company’s stock valued at $145,000 after acquiring an additional 548 shares in the last quarter. Cardinal Capital Management lifted its position in shares of Charles River Laboratories Intl. by 7.0% in the 3rd quarter. Cardinal Capital Management now owns 8,447 shares of the medical research company’s stock valued at $912,000 after acquiring an additional 549 shares in the last quarter. Finally, Norris Perne & French LLP MI lifted its position in shares of Charles River Laboratories Intl. by 0.6% in the 3rd quarter. Norris Perne & French LLP MI now owns 98,882 shares of the medical research company’s stock valued at $10,681,000 after acquiring an additional 577 shares in the last quarter. Institutional investors and hedge funds own 97.13% of the company’s stock.

CRL has been the subject of several research analyst reports. Argus initiated coverage on shares of Charles River Laboratories Intl. in a research report on Wednesday, December 13th. They issued a “buy” rating and a $120.00 price target for the company. Bank of America reduced their price target on shares of Charles River Laboratories Intl. from $117.00 to $115.00 and set a “buy” rating for the company in a research report on Friday, November 10th. Zacks Investment Research upgraded shares of Charles River Laboratories Intl. from a “hold” rating to a “buy” rating and set a $129.00 price target for the company in a research report on Tuesday, October 24th. ValuEngine downgraded shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research report on Friday, November 10th. Finally, Credit Suisse Group restated a “neutral” rating and issued a $112.00 price target (up previously from $95.00) on shares of Charles River Laboratories Intl. in a research report on Monday, October 16th. Eight research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Charles River Laboratories Intl. presently has an average rating of “Hold” and a consensus price target of $112.58.

Shares of Charles River Laboratories Intl. Inc (NYSE CRL) opened at $101.99 on Tuesday. Charles River Laboratories Intl. Inc has a 12-month low of $81.81 and a 12-month high of $119.05. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.88 and a quick ratio of 1.62. The stock has a market cap of $4,725.26, a P/E ratio of 24.88, a price-to-earnings-growth ratio of 1.46 and a beta of 0.74.

In other Charles River Laboratories Intl. news, Director Robert J. Bertolini sold 3,609 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $110.22, for a total value of $397,783.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Online Communications Bdirect sold 131,000 shares of the firm’s stock in a transaction on Thursday, January 18th. The shares were sold at an average price of $0.29, for a total transaction of $37,990.00. In the last quarter, insiders sold 195,673 shares of company stock valued at $2,644,046. Insiders own 2.20% of the company’s stock.

WARNING: This piece was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://theolympiareport.com/2018/02/13/charles-river-laboratories-intl-inc-crl-shares-sold-by-meeder-asset-management-inc.html.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories Intl. Inc (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.